Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evolus, Inc.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.
AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.
- OTC, Consumer
- Other Names / Subsidiaries
- ALPHAEON Corporation
- AEON Biopharma, Inc.
- SCH-AEON, LLC
- Strathspey Crown Holdings, LLC
- Strathspey Crown Holdings Group, LLC